Our findings reveal a novel cardiomyocyte‐specific USP20‐STAT3‐CARM1 (coactivator‐associated arginine methyltransferase 1) axis that regulates cardiac hypertrophy and heart failure, and position USP20 as a potential therapeutic target for pathological cardiac hypertrophy and heart failure. Here, CARM1 is linked to cardiac hypertrophy.